Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASCO: Presentations Showcase Possibilities Of Next-Generation Cell Therapies

Sessions Highlight Off-The-Shelf, CRISPR Approaches

Executive Summary

An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.

You may also be interested in...



Affimed’s AFM13 Data Show Potential Of NK Cell Approach

Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.

From Auto To Allo: Poseida Tries To Pick The Winning CAR-T Team

The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.

Fate’s Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed

While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel